The DOI matches its Crossref record; 159 of the 159 references it cites were found in a registry or an index.
The Lancet Commission on prostate cancer: planning for the surge in cases
Open accessAbstract
Executive summaryProstate cancer is the most common cancer in men in 112 countries, and accounts for 15% of cancers.In this Commission, we report projections of prostate cancer cases in 2040 on the basis of data for demographic changes worldwide and rising life expectancy.Our findings suggest that the number of new cases annually will rise from 1•4 million in 2020 to 2•9 million by 2040.This surge in cases cannot be prevented by lifestyle changes or public health interventions alone, and governments need to prepare strategies to deal with it.We have projected trends in the incidence of prostate cancer and related mortality (assuming no changes in treatment) in the next 10-15 years, and make recom mendations on how to deal with these issues.For the Commission, we established four working groups, each of which examined a different aspect of prostate cancer: epidemiology and future projected trends in cases, the diagnostic pathway, treatment, and management of advanced disease, the main problem for most men diagnosed with prostate cancer worldwide.Throughout we have separated problems in highincome countries (HICs) from those in lowincome and middle income countries (LMICs), although we acknowledge that this distinction can be an oversimplification (some rich patients in LMICs can access highquality care, whereas many patients in HICs, especially the USA, cannot because of inadequate insurance coverage).The burden of disease globally is already substantial, but options to improve care are already available at moderate cost.We found that late diagnosis is widespread worldwide, but especially in LMICs, where it is the norm.Early diagnosis improves prognosis and outcomes, and reduces societal and individual costs, and we recommend changes to the diagnostic pathway that can be immediately implemented.For men diagnosed with advanced disease, optimal use of available technologies, adjusted to the resource levels available, could produce improved outcomes.We also found that demographic changes (ie, changing age structures and increasing life expectancy) in LMICs will drive big increases in prostate cancer, and cases are also projected to rise in highincome countries.This projected rise in cases has driven the main thrust of our recommendations throughout.Dealing with this rise in cases will require urgent and radical interventions, particularly in LMICs, including an emphasis on education (both of health professionals and the general population) linked to outreach programmes to increase awareness.If implemented, these inter ventions would shift the case mix from advanced to earlierstage disease, which in turn would necessitate different treatment approaches: earlier diagnosis would prompt a shift from palliative to curative therapies based around surgery and radiotherapy.Although ageadjusted mortality from prostate cancer is falling in HICs, it is rising in LMICs.And, despite large, well known differences in disease incidence and mortality by ethnicity (eg, incidence in men of African heritage is roughly double that in men of European heritage), most prostate cancer research has disproportionally focused on men of European heritage.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21660 · Cited by 108,699
Self-citationBray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21492 · Cited by 84,109
Self-citationCancer statistics for the year 2020: An overview
Ferlay, J., Colombet, M., Soerjomataram, I., Parkin, D. M., Piñeros, M., Znaor, A., & Bray, F. (2021) · International Journal of Cancer · doi:10.1002/ijc.33588 · Cited by 5,689
Self-citationAbiraterone and Increased Survival in Metastatic Prostate Cancer
de Bono, J. S., Logothetis, C. J., Molina, A., Fizazi, K., North, S., Chu, L., Chi, K. N., Jones, R. J., Goodman, O. B., Saad, F., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1014618 · Cited by 4,407 · cited 1×
“Neither governments nor large media and technology companies are widely trusted by the general public, often for well founded reasons, as evidenced by controversies around election interference, government 5G contracts, and claims of socalled fake news, etc.”
High-quality health systems in the Sustainable Development Goals era: time for a revolution
Kruk, M. E., Gage, A. D., Arsenault, C., Jordan, K., Leslie, H. H., Roder-DeWan, S., Adeyi, O., Barker, P., Daelmans, B., Doubova, S. V., et al. (2018) · The Lancet Global Health · doi:10.1016/s2214-109x(18)30386-3 · Cited by 4,057
Screening and Prostate-Cancer Mortality in a Randomized European Study
Schröder, F. H., Hugosson, J., Roobol, M. J., Tammela, T. L. J., Ciatto, S., Nelen, V., Kwiatkowski, M., Lujan, M., Lilja, H., Zappa, M., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810084 · Cited by 4,014
Global Surgery 2030: evidence and solutions for achieving health, welfare, and economic development
Meara, J. G., Leather, A. J. M., Hagander, L., Alkire, B. C., Alonso, N., Ameh, E. A., Bickler, S. W., Conteh, L., Dare, A. J., Davies, J., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(15)60160-x · Cited by 3,851
Ahmed, H. U., El-Shater Bosaily, A., Brown, L. C., Gabe, R., Kaplan, R., Parmar, M. K., Collaco-Moraes, Y., Ward, K., Hindley, R. G., Freeman, A., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(16)32401-1 · Cited by 3,284
Self-citationMRI-Targeted or Standard Biopsy for Prostate-Cancer Diagnosis
Kasivisvanathan, V., Rannikko, A. S., Borghi, M., Panebianco, V., Mynderse, L. A., Vaarala, M. H., Briganti, A., Budäus, L., Hellawell, G., Hindley, R. G., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1801993 · Cited by 3,091
Self-citationMortality Results from a Randomized Prostate-Cancer Screening Trial
Andriole, G. L., Crawford, E. D., Grubb, R. L., Buys, S. S., Chia, D., Church, T. R., Fouad, M. N., Gelmann, E. P., Kvale, P. A., Reding, D. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810696 · Cited by 2,906
Cited by
Saha, A., Bosma, J. S., Twilt, J. J., van Ginneken, B., Bjartell, A., Padhani, A. R., Bonekamp, D., Villeirs, G., Salomon, G., Giannarini, G., et al. (2024) · The Lancet Oncology · doi:10.1016/s1470-2045(24)00220-1 · Cited by 346
Self-citationRecent Patterns and Trends in Global Prostate Cancer Incidence and Mortality: An Update
Schafer, E. J., Laversanne, M., Sung, H., Soerjomataram, I., Briganti, A., Dahut, W., Bray, F., & Jemal, A. (2025) · European Urology · doi:10.1016/j.eururo.2024.11.013 · Cited by 269
Self-citationMechanistic study of cancer drug delivery: Current techniques, limitations, and future prospects
Imtiaz, S., Ferdous, U. T., Nizela, A., Hasan, A., Shakoor, A., Zia, A. W., & Uddin, S. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.117535 · Cited by 119
Gillessen, S., Murphy, L., James, N. D., Sachdeva, A., El-Taji, O., Abdel-Aty, H., Adler, A. I., Amos, C., Attard, G., Varughese, M., et al. (2025) · The Lancet Oncology · doi:10.1016/s1470-2045(25)00231-1 · Cited by 28
Self-citation
Metadata
- Authors
- James, N. D., Tannock, I., N'Dow, J., Feng, F., Gillessen, S., Ali, S. A., Trujillo, B., Al-Lazikani, B., Attard, G., Bray, F., Compérat, E., Eeles, R., Fatiregun, O., Grist, E., Halabi, S., Haran, Á., Herchenhorn, D., Hofman, M. S., Jalloh, M., Loeb, S., MacNair, A., Mahal, B., Mendes, L., Moghul, M., Moore, C., Morgans, A., Morris, M., Murphy, D., Murthy, V., Nguyen, P. L., Padhani, A., Parker, C., Rush, H., Sculpher, M., Soule, H., Sydes, M. R., Tilki, D., Tunariu, N., Villanti, P., & Xie, L.-P.
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2024-04
- Volume
- 403
- Issue
- 10437
- Pages
- 1683-1722
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- OpenAlex
- W4393926609
- Cited by
- 738
- References
- 159
- FWCI
- 188.05
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Lancet Commission on prostate cancer: planning for the surge in cases. https://app.cochat.ai/papers/10.1016/s0140-6736(24)00651-2
- The paper
- James, N. D., Tannock, I., N'Dow, J., Feng, F., Gillessen, S., Ali, S. A., Trujillo, B., Al-Lazikani, B., Attard, G., Bray, F., Compérat, E., Eeles, R., Fatiregun, O., Grist, E., Halabi, S., Haran, Á., Herchenhorn, D., Hofman, M. S., Jalloh, M., . . . Xie, L.-P. (2024). The Lancet Commission on prostate cancer: planning for the surge in cases. The Lancet. https://doi.org/10.1016/s0140-6736(24)00651-2
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.